Trials / Completed
CompletedNCT04631276
Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Taisho Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the following items by PET examination in Japanese heathy adult male subjects who received single oral administration of TS-091 in an unblinded manner. 1. Relationship between plasma concentration and H3 receptor-occupancy of TS-091 2. Time course changes in H3 receptor-occupancy of TS-091
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TS-091 | Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder) |
Timeline
- Start date
- 2014-12-11
- Primary completion
- 2015-12-16
- Completion
- 2015-12-16
- First posted
- 2020-11-17
- Last updated
- 2025-02-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04631276. Inclusion in this directory is not an endorsement.